Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options.